Correction to: Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy

Alexandra Langlois1, Marie-Hélène Laervinge2, Hélène Leroux2, Kerstin Killer2, Pauline Azzano1, Louis Paradis1,3, Kathryn Samaan1, Jonathan Lacombe-Barrios1, Thomas Eiwegger4, Julia Upton4, Gordon Sussman5, Thomas Poder6,7, Benoît Mâssé2,8, Anne Des Roches1,2 and Philippe Bégin1,2,3*

Correction to: Allergy Asthma Clin Immunol (2020) 16:25
https://doi.org/10.1186/s13223-020-00419-z

The names of Thomas Eiwegger, Julia Upton, Gordon Sussman and Thomas Poder were inadvertently omitted from the authorship of the original article [1]. Thomas Eiwegger, Julia Upton, Gordon Sussman and Thomas Poder had participated in meetings and exchanges regarding the trial design and their names are added to recognize their contribution to the conception of the protocol.

The full and correct authorship has been updated in the original article and included in the author list of this Correction article.

The ‘Competing interests’ section is also corrected here to read: The authors declare no conflict of interest related to the study. KS reports personal fees from Novartis, Aralez, CSL Behring, Sanofi, Pedipharma, GSK, Genentech, DBV technologies, Aimmune, Astrazeneca, Stallergenes, Mercck, Pfizer, Dyax, Biocryst, Greencross, Kendrion, Shire, Leopharma, Regeneron, mDbriefCase and grants from Novartis, GSK, Genentech, DBV technologies, Aimmune, CSL Behring, Astrazeneca, Stallergenes, Merck, Pfizer, Dyax, Biocryst, Greencross, Kendrion, Leo Pharma, Regeneron, Sanofi, Blueprint, ALK, Amgen, Clinthia outside the submitted work. ADR reports grants from Merk and ALK outside the submitted work. PB reports personal fees from Novartis, Pfizer, Sanofi, ALK and Aralez, as well as grants from DBV technologies, Regeneron and Sanofi outside the submitted work.

Author details
1 Department of Allergy and Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada. 2 Centre Hospitalier Sainte-Justine Research Center, Montreal, QC, Canada. 3 Department of Allergy and Immunology, Centre Hospitalier de l’Université de Montréal, 3175 Chemin de la Côte Sainte-Catherine, Montreal, QC H3T1CS, Canada. 4 Division of Immunology and Allergy, Department of Paediatrics, The Hospital for Sick Children, The University of Toronto, Toronto, ON, Canada. 5 Gordon Sussman Clinical Research, Toronto, ON, Canada. 6 Department of Management, Evaluation and Health Policy, School of Public Health, Université de Montréal, Montreal, QC, Canada. 7 Research Center of the Institut Universitaire de l’Assurance Maladie du Québec, Canada. ALK-Abelló, Kaleo, and grants from Toronto SickKids Foundation, DBV technologies, Regeneron, and ALK-Abelló outside the submitted work. GS reports personal fees from Novartis, Aralez, CSL Behring, Sanofi, Pedipharma, GSK, Genentech, DBV technologies, Aimmune, Astrazeneca, Stallergenes, Merck, Pfizer, Dyax, Biocryst, Greencross, Kendrion, Shire, Leopharma, Regeneron, mDbriefCase and grants from Novartis, GSK, Genentech, DBV technologies, Aimmune, CSL Behring, Astrazeneca, Stallergenes, Merck, Pfizer, Dyax, Biocryst, Greencross, Kendrion, Leo Pharma, Regeneron, Sanofi, Blueprint, ALK, Amgen, Clinthia outside the submitted work. ADR reports grants from Merk and ALK outside the submitted work. PB reports personal fees from Novartis, Pfizer, Sanofi, ALK and Aralez, as well as grants from DBV technologies, Regeneron and Sanofi outside the submitted work.

The original article can be found online at https://doi.org/10.1186/s13223-020-00419-z.*Correspondence: philippe.begin@umontreal.ca
3 Department of Allergy and Immunology, Centre Hospitalier de l’Université de Montréal, 3175 Chemin de la Côte Sainte-Catherine, Montreal, QC H3T1CS, Canada
Full list of author information is available at the end of the article

© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Reference

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.